Elocom (mometasone furoate) ointment 15 g.

Description

Elocom ointment 15 g. Storage
active substance: mometasone furoate;

1 g of ointment contains mometasone furoate 1 mg;

Elocom ointment 15 g. Excipients: hexylene glycol, purified water, dilute phosphoric acid, propylene glycol stearate, white wax, white soft paraffin.

Elocom ointment 15 g. Dosage form
Ointment.

Main physical and chemical properties: white or almost white opaque ointment, without foreign inclusions.

Pharmacotherapeutic group
Corticosteroids for use in dermatology.

ATX code D07A C13.

Pharmacological properties

Pharmacodynamics.

Mometasone furoate is a synthetic glucocorticosteroid for topical use with anti-inflammatory, antipruritic and antiexudative effects.

Pharmacokinetics.

Pharmacokinetic studies have shown that systemic absorption after topical application of mometasone furoate 0.1% is minimal; approximately 0.4% of the administered dose is eliminated from the body within 72 hours after application. It was almost impossible to establish the nature of the metabolites due to the small amount present in blood plasma and secretions.

Indication
Inflammatory phenomena and itching in dermatoses treated with corticosteroids, including psoriasis (except for common plaque psoriasis) and atopic dermatitis, in adults and children over 2 years of age.

Contraindication
Elocom® is contraindicated in rosacea, acne vulgaris, skin atrophy, perioral dermatitis, perianal and genital itching, diaper rash, bacterial (eg impetigo, pyoderma), viral (eg herpes simplex, herpes zoster, shingles and shingles) mollusk), parasitic and fungal (eg candida or dermatophyte) infections, tuberculosis, syphilis or post-vaccination reactions. Elocom® should not be applied to wounds or ulcerated skin. The drug is contraindicated in patients with hypersensitivity to any of the components of the drug or to other glucocorticosteroids.

Interaction with other medicinal products and other forms of interaction
Not installed.

Features of application
In case of irritation or sensitization, treatment should be discontinued and appropriate therapy instituted.

In case of concomitant skin infection, an appropriate antifungal or antibacterial drug should be used. If positive dynamics cannot be achieved within a short time, Elocom® ointment should be discontinued until the infection is completely eliminated.

Systemic topical administration of various glucocorticosteroids may cause reversible suppression of hypothalamic-pituitary-adrenal function with possible glucocorticosteroid insufficiency after discontinuation of treatment. Some patients may experience Cushing’s syndrome, hyperglycemia, and glucosuria.